Failure-to-Detect Claims Against Dermopathologists
In both PA and NJ, a claim for medical malpractice is not cognizable unless the "target" physician owes the plaintiff a duty of care. The duty of care owed by a dermopathologist arises by virtue of his or her willingness to undertake interpreting the cutaneous pathology slides.
Features
Evidence-Based Medicine in Medical Malpractice Litigation
The evolution of evidence-based medicine should cast doubt upon advocacy that masquerades as science, and put courts in the position of deciding when science should prevail.
Five Steps to Building Your Medical Malpractice Risk 'Crash Cart'
Sometimes, despite best-laid treatment plans, unforeseen and unforeseeable medical complications still arise. Then you need a "crash cart.
Disclosure of ADR Affiliation
California's Second District Court of Appeal recently established a bright-line rule when it held that a lawyer's membership in the ADR provider deciding his case must be disclosed to the other side.
The Duty to Notify an Excess Carrier: Considerations for Defense Counsel
The relationship between a primary and excess insurance carrier within the context of a catastrophic medical malpractice litigation is fraught with possible pitfalls.
Columns & Departments
Verdicts
In-depth analysis of a recent key case.
Columns & Departments
Drug & Device News
News of importance for you and your practice.
The Lawyer in the Examination Room
Last month, we began discussion of the question: "When the court orders a litigant to undergo a psychological examination, is it proper, or permissible, for that party's attorney to attend the session?" The discussion concludes herein.
Need Help?
- Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
- Need other assistance? email Customer Service or call 1-877-256-2472.
MOST POPULAR STORIES
- Protecting Innovation in the Cyber World from Patent TrollsWith trillions of dollars to keep watch over, the last thing we need is the distraction of costly litigation brought on by patent assertion entities (PAEs or "patent trolls"), companies that don't make any products but instead seek royalties by asserting their patents against those who do make products.Read More ›
- Meet the Lawyer Working on Inclusion Rider LanguageAt the Oscars in March, Best Actress winner Frances McDormand made “inclusion rider” go viral. But Kalpana Kotagal, a partner at Cohen Milstein Sellers & Toll had already worked for months to write the language for such provisions. Kotagal was developing legal language for contract provisions that Hollywood's elite could use to require studios and other partners to employ diverse workers on set.Read More ›
- From the PTO to the FDA: What to Consider When Branding Clinical TrialsThe legal implications of branding generally arise initially for companies during the process of selecting a company name and any initial product or service names. For drug development companies, however, careful consideration should also be paid to the implications of branding a clinical trial.Read More ›
- Use of Deferred Prosecution Agreements In White Collar InvestigationsThis article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.Read More ›